Company Snapshot

Investment Thesis

Edwards Lifesciences pioneers structural heart therapies including transcatheter aortic valve replacement (TAVR) and critical care monitoring. Aging populations and innovation drive double-digit growth.

  • TAVR Leadership: Sapien valve franchise maintains clinical/market share leadership.
  • Structural Heart Innovation: Transcatheter mitral/tricuspid therapies expand TAM.
  • Critical Care: Hemodynamic monitoring and Smart Recovery platforms offer recurring revenue.

Strategic Mix

Transcatheter Aortic Valve Replacement Sapien valve systems
Transcatheter Mitral/Tricuspid Pascal/other emerging solutions
Surgical Structural Heart Surgical valves and repair products
Critical Care Monitoring systems and disposables

Mix reflects Edwards’ structural heart and critical care businesses.

Recent Performance

MTD TBD
QTD TBD
YTD TBD
5Y TBD

Maxim is cueing up returns data for this security. Once the nightly supported.csv job runs, these metrics will auto-populate.

Strategic Insights

Clinical Evidence

Ongoing trials expand indications to moderate risk/younger patients.

Global Penetration

International adoption accelerates as training centers proliferate.

Digital Integration

AI-powered monitoring and hospital partnerships enhance outcomes.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...